The Lancet Oncology 2024

7 papers
In 2024, research in The Lancet Oncology focused on the clinical integration of artificial intelligence and advanced imaging. Key themes included bridging the gap between AI development and clinical utility, standardizing radiomics for reproducible biomarkers, and addressing temporal dataset shifts in machine learning. A significant portion of the work addressed diagnostic accuracy and response assessment, exemplified by the AI-RANO recommendations for neuro-oncology and the PI-CAI study comparing AI performance to radiologists in prostate cancer detection. The year’s publications also explored decentralized data collaboration through federated learning and the generalization of imaging models across clinical sites. Specific research included deep learning for gene mutation prediction in lung cancer and the use of PSMA-PET to redefine disease staging in prostate cancer. Clinical trials, such as the FASTRACK II phase 2 trial on stereotactic ablative body radiotherapy for kidney cancer, were also featured. Key contributors included Philipp Kickingereder, Klaus Maier-Hein, and Christos Davatzikos, reflecting a collaborative effort to improve oncological diagnostics and treatment protocols through validated machine learning applications.

Top Research Directions

The 7 research directions with The Lancet Oncology 2024 papers, ranked by paper count, next to 2023. Share is the fraction of the edition’s papers in the direction.

#Direction20242023Share 2024Share 20232023 rank
1Bridging the Clinical Translation Gap for Machine Learning1014.3%0.0%—
2Decentralized Model Training via Federated Learning1014.3%0.0%—
3Differentiating Pseudoprogression from True Tumor Growth1014.3%0.0%—
4External Cohort Validation for Predictive Models1014.3%0.0%—
5Harmonizing Radiomic Features Across Medical Imaging Platforms1014.3%0.0%—
6Temporal Dataset Shift in Machine Learning Models1014.3%0.0%—
7The Pathological Generalization Gap in Medical Imaging1014.3%0.0%—

Download all directions as CSV

Institutions

Institutions credited by The Lancet Oncology 2024 papers: a paper credits every institution named in its affiliations, once. 20 institutions share 1 credited papers.

#InstitutionPapersShare20232023 rank
100g1d7b60 1100.0%0—
2Brigham and Women's Hospital 1100.0%0—
3Duke University 1100.0%0—
4German Cancer Research Center 1100.0%0—
5Harvard Medical School 1100.0%0—
6Indiana University 1100.0%0—
7Indiana University Indianapolis 1100.0%0—
8King's College Hospital NHS Foundation Trust 1100.0%0—
9King's College London 1100.0%0—
10Maastricht University 1100.0%0—
11New York University 1100.0%0—
12NYU Grossman Long Island School of Medicine 1100.0%0—
13RWTH Aachen University 1100.0%0—
14Technical University of Munich 1100.0%0—
15University Hospital Bonn 1100.0%0—
16University Hospital Cologne 1100.0%0—
17University of Bonn 1100.0%0—
18University of California, San Francisco 1100.0%0—
19University of Pittsburgh 1100.0%0—
20University of Wisconsin–Madison 1100.0%0—

Download all institutions as CSV

About this data

Papers. The Lancet Oncology 2024 lists 7 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2023 use shares, since the edition went from 3 to 7 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 7 papers (14.3%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “The Lancet Oncology 2024”, https://lacuna.tiptreesystems.com/venue/the-lancet-oncology/2024.

Top Authors

AuthorPapers
Klaus Maier-Hein2
Bing He1
Erich Kobler1
Jens Kleesiek1
Jianhua Yao1
Junzhou Huang1
Yu Zhao1

Papers

Title
Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study
Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial